
é°è¬è« vs ã¯ã¯ãã³ã«ã«ã
é°è¬è«ãªããŠèšèããããŸãããããããã®èšèã¯ãããã䜿ããªããªã£ãŠããŸãæ°ãããŸããé°è¬ãæããã«ãªããããŠãæ¢ã«é°è¬ã§ã¯ãªããªã£ãŠããããã«æãããã§ãã代ãã£ãŠåºãŠããã®ã¯ãããã«ä¹ããããŠçãŸããŠãããã¯ã¯ãã³ã«ã«ããšããäžççéå£ã§ã¯ãªãããšæããŠãªããŸããã
ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒ
ãããããæ¥æ¬ã§ãã¯ã¯ãã³æ¥çš®ãæ¬æ ŒåããŠããŸãããã¯ã¯ãã³ã«ã€ããŠã¯ãå€ãã®çåãæ®ã£ãŠãããç§ãããããçåãæããªãåŽã®äžäººã§ããã¯ã¯ãã³ããæ°åã³ãããŠã€ã«ã¹ãæã蟌ãåãæã§ãã£ãŠãããããããã«è¶ããããšã¯ãããŸãããããããã©ãããŠãããã¯æããªãã®ã§ãã
ãã ãããããªããšãèšããšãã¯ã¯ãã³ãæšãé²ããã人ã ãããããã倧å€éªéã§ãããããŠãã¯ã¯ãã³ãçã人ã ã¯ãé°è¬è«ãä¿¡ããè¿·æãªé£äžãšããã¬ããã«ã貌ãããããã«ãªã£ãŠããŸãããããããæå³ã§ã¯ãããããç§ãç«æŽŸãªé°è¬è«è ãšããããšã«ãªãããšæããŸãã
ãšããã§ããã®æã®é°è¬è«ã®ã¬ããã«è²Œãã«ã¯ã以äžã®ãããªç¹åŸŽããããŸãã
ïŒïŒæ¥µç«¯ãªäŸãè«ã£ãŠãå
šäœãäžæ¬ãã«ããŠãã¡åºãããã
ïŒïŒçããããªãçåã«ã€ããŠã¯ã培åºçã«è°è«ãé¿ãã
äŸãã°ãã1ãã«ã€ããŠã¯ãããªæãã§ããããã
éè¡äººã«é ã£ãŠãããã©ã§ã¯ãã³ããã¯ãã ã®é¢šéªãäžçã®è³æ¬å®¶ãååœã®æ¿åºãæããã§ã£ã¡äžããŠããããã¯ã¯ãã³ã§äººéã«ãã€ã¯ãããããåã蟌ãã®ãç®çããªã©ãšäž»åŒµã
â»èªå£²æ°èãªã³ã©ã€ã³ãã¯ã¯ãã³ã§ãé»å¹ã人é¡ç®¡çãã人å£åæžãçããâŠã¯ã³ããé°è¬è«ãåæã®åŠšãã«ãã2021幎5æ16æ¥ããåŒçš
ãããã®äž»åŒµã«ã€ããŠã现ããè«æ ãèŠãŠãããšãäžæŠã«ã¯åŠå®ãããªãéšåããããããããŸããïŒæ£ç¢ºã«ã¯ãããããããªãããšãå€ããšããæ¹ãé©åãïŒïŒããã ãã±ã£ãšèŠãããããæ¥µç«¯ãªãã®ã«èŠããã§ããããæ®æ®µãããã¹ã¡ãã£ã¢ã°ããèŠãŠãã人ãããããšãã®ã§ããšããå 容ã ãšæããŸããããããéšåãåãåºããŠããã»ããããã€ãããããã§ããããšããå ·åã§ããããå šäœïŒã¯ã¯ãã³ã«å察ãã人ïŒãé°è¬è«è ãšæ±ºãã€ããããã§ãã
ãã ããå®ã¯äžèšã®ããã«ã®ã§ããšãããããªå 容ã«è¡ãã€ããŸã§ã«ã¯ããã¹ã¡ãã£ã¢ãçããŠããªãçåãäºå®ããåå ãšããŠããã®ã§ãããããã2ãã®éšåã§ããããã¯ããããã¹ã¡ãã£ã¢ã®å ±éããªãèªç±ããªã©ãšãæ¶æãããŸããããããçåãäºå®ãç©ã¿éããŠãããšãçµè«ãšããŠãäžçã®è³æ¬å®¶ãååœã®æ¿åºãæããã§ã£ã¡äžããŠããããšãã話ã«ãŸã§ããã©ãçãåŸãŠããŸããšããããšã§ãã
äŸãã°ãæ¢ã«ã€ã³ããå§ããšããå€ãã®å°åã§ãæ°åã³ãããŠã€ã«ã¹ã«å¹æãçºæ®ããŠããã€ãã«ã¡ã¯ãã³ããããå ±éããããŠæ¿åºã®ã¹ã¿ã³ã¹ã§ããäžææã倧å€ãªæ»è æ°ãåºããŠããããã¯ã«é¥ã£ãŠãããšãããŠããã€ã³ãã§ãããã€ãã«ã¡ã¯ãã³ãæå ¥ããããšã§ãäºæ ã¯æ²éåããŸããã
ã¿ãã«ããã¥å·ã¯ãç§ãã¡ã®ç¥ãéããã€ãã«ã¡ã¯ãã³ãçŠæ¢ããå¯äžã®ã€ã³ãã®å·ãšãªããŸãããŸããæµè¡ãå éããŠããå¯äžã®åœã§ããããŸãã
ïŒäžç¥ïŒ
5æ16æ¥ãã€ã³ãã®ç¶æ³ã¯æããã«æ¹åãããŸããããåœå ã®æ°èŠææè ã®13ïŒ ãã€ãŸã100äžäººãããã®1æ¥ã®ææè æ°ã500人ãè¶ ããã¿ãã«ã»ããŒãã¥å·ã§ã¯æ¹åãããŸããã§ããã
ïŒäžç¥ïŒ
ä»ã®å·ã§ã¯ã€ãã«ã¡ã¯ãã³ã宿çã«æäžããããšã§ç¶æ³ãæ¹åãããŠããã ãã«ãã¿ãã«ããã¥å·ã®ç¶æ³ã¯ããäžå±€ã²ã©ããã®ãšãªã£ãŠããŸãã
â»AGORA VOXãVariant indien : Ivermectine 1 / OMS 0ã2021幎5æ18æ¥ããåŒçšïŒæ©æ¢°ç¿»èš³ïŒ
ã€ã³ãã ãã§ã¯ãããŸãããäžçäžã®è³ããšããã§ãã€ãã«ã¡ã¯ãã³ãæäžãããŠãç¶æ³ãæ¹åãããŠããäºäŸã¯ããããåºãŠããŠããŸãããããããã¹ã³ãã¯ã€ã³ãã倧å€ãªç¶æ³ã«é¥ã£ãããšãå ±éããŠããã€ãã«ã¡ã¯ãã³ã§å±æ©ãè±ãããšãããã¥ãŒã¹ã¯æµããŸãããæ¿åºããã€ãã«ã¡ã¯ãã³ã«ã¯ç§åŠçæ ¹æ ãäžååã ãšããå§¿å¢ãå šã厩ããªããŸãŸã§ããŸãã
ãã£ãããªã®ã§ãAlzhackerããã®æçš¿ã§ãã€ãã«ã¡ã¯ãã³ã«é¢ããŠãæ¿åºããã¹ã³ããçããããŠããªãçåããããŸããé·ãã§ãããåŒçšããŠãããŸãã
ã€ãã«ã¡ã¯ãã³ãå±éºã ãšæãã®ã§ããã°ããããã11ã®ç°åžžã®çã®åå ã説æããå¿ èŠãããããã®ãã¡ã®1ã€ã§ã説æã§ããªããã°ã誰ã圌ã®è©±ãçå£ã«èãå¿ èŠã¯ãªãã ãããçµå±ãå察ã®èŠç¹ãæã€äººã¯ããã®äžã®ã©ããäžã€ãåãäžããŠãããããªèª¬æãããããšããã§ããªãã®ã ã
â Alzhacker (@Alzhacker) May 17, 2021
1.ã¡ãã·ã³ã§ã¯ã€ãã«ã¡ã¯ãã³ã®æ®åã奚å±ããŠãããããã®ç é¢ã¯ã»ãŒç©ºã£ãœã ãã€ãã«ã¡ã¯ãã³ã§ãªããã°ããªããã®ãããªå¥è·¡ãèµ·ããã®ã§ããããïŒããã§ã¯ãã1ã€ã®ç é¢ã®è©±ã§ã¯ãªããã¡ãã·ã³ã®ã»ãŒãã¹ãŠã®ç é¢ã®è©±ãããŠããã
2.ãã¡ãªãŒãå»åž«ãšã¿ã€ãœã³å»åž«ã¯ã ããããã·ã¯ãããã³ãšã€ãã«ã¡ã¯ãã³ã䜿ã£ãŠ6,000人以äžã®ã³ãŒãããæ£è ãæ²»çããŠããŠãå ¥é¢çããŒãã«è¿ãã®ã¯ãªãã§ããããïŒWHOã«ããã°ãã©ã¡ãã®è¬ãäºæ ãæªåããããšããã
3.ãã«ãŒãã¡ãã·ã³ããžã³ãããšãªã©ã®åœã§ã®èŽæ»çã®å±±ãšè°·ã¯ãã€ãã«ã¡ã¯ãã³ã®æµéãšå€±å¹ã«çžé¢ããŠããããããã€ãã«ã¡ã¯ãã³ã®é åžã倱å¹ããããã®åœ±é¿ãåŒãèµ·ãããã®ã§ã¯ãªããšããããæ¬åœã®åå ã¯äœã ã£ãã®ã ãããïŒ
4.ã¡ãã·ã³ã§çºè¡šããã20äžäººä»¥äžã察象ãšããç ç©¶ã§ã¯ãã€ãã«ã¡ã¯ãã³æ²»çããããæçšãã人ã®å ¥é¢ä»¶æ°ã52%ä»¥äžæžå°ãããæ²»çããããåå ã§ãªããšããããäœãåå ãªã®ã ãããïŒ
5.åœéçãªå°éå®¶éå£ãè¡ã£ãBIRDã®ã·ã¹ãããã£ãã¯ã¬ãã¥ãŒã§ã¯ããã¹ãŠã®ããŒã¿ãæ€èšããã€ãã«ã¡ã¯ãã³ãå°å ¥ãã¹ãã ãšçµè«ã¥ããŠãããå ¬è¡šãããŠãæç®ã«ããäžçäžã®ãã¬ããªã³ããµãŒããŒã«ãããã®ç ç©¶ã®æ¬ é¥ãææããè«æã¯ãªããããã¯ãªããªã®ãïŒ
6.ã€ãã«ã¡ã¯ãã³ãæ¯æããã³ãŒãªãŒå士ã®å æ¬çãªãã©ãã£ãã¬ãã¥ãŒã¯ã2ã€ã®ç°ãªããžã£ãŒãã«ã§ã®æ»èªãééããã€ãã«ã¡ã¯ãã³ã¯ã³ãŒãããã®ãã¹ãŠã®æ®µéã§æå¹ãšçµè«ã¥ããŠããããã圌ãã®çµè«ã«æ¬ é¥ãããã®ãªããæ»èªãè¡ã£ã3äººã®æ¿åºé«å®ã®ç§åŠè ã¯ããªããã®è«æãåçããã®ãïŒ
7.ãŠãã¿ã«ã»ãã©ããŒã·ã¥å·ã®ä¿å¥åœå±ãèšé²ãæ®ããŠãããäºé²è¬ãšããŠã®ã€ãã«ã¡ã¯ãã³ã¯COVID-19ã®ææçãšæ»äº¡çãäžãããæ¿åºã®çºè¡šã§ããã誰ãããã«ç°è°ãå±ããŠããªãã圌ããééã£ãŠãããšããããæ¬åœã®åå ã¯äœãªã®ãïŒ
8.ãã«å士ã¯WHOã®äŸé Œãåããã€ãã«ã¡ã¯ãã³ã®å®¢èгçãªèª¿æ»ãè¡ã£ãã圌ã¯ã€ãã«ã¡ã¯ãã³ã¯å¹³åããŠ75%ã®å¹æããããšçµè«ã¥ãããããã®åŸãç ç©¶ã¹ãã³ãµãŒã«ãã£ãŠçµè«ãæžãçŽãããããå€ãã®èšŒæ ãå¿ èŠã§ãããšæšå¥šããããšã«åæããããã«å士ã«äœãèµ·ãã£ãã®ãïŒãªã圌ã¯å§¿ãæ¶ããã®ãïŒ
9.ããè¬ãå¹ããªãã®ã§ããã°ãå°ãªããšã1ã€ã®DB-RCTã«ãããŠãéåžžã«çµ±èšçã«ææãªçšéåå¿é¢ä¿ããã£ãããšãã©ã説æããã®ãïŒããç ç©¶ã§(p = 0.0066) ãšpå€ãéåžžã«äœãã誰ããéãè¯ãã£ãããšã¯èšããªããè¬ãäœãäœçšããªãã®ãªãããªãäœãpå€ãåºãã®ã ãããïŒ
10.ããè¬ãå¹ããªãã®ã§ããã°ããªããªã¢ã«ã¯ãŒã«ãã§ãã®è¬ãåŠæ¹ããå»åž«ã¯çãå ¥é¢çã®äœäžãå ±åããã®ã ãããïŒãäžçäžã®ã©ããã§ã€ãã«ã¡ã¯ãã³ãåŠæ¹ãå§ããå»åž«ãããã®å»åž«ã®å ¥é¢çãäžãããªããããšãã£ãŠãã€ãã«ã¡ã¯ãã³ãåºãã®ãããããšããã±ãŒã¹ã¯ããã®ã ãããïŒ
11.ã€ã³ãAIMSã®ç§åŠè ãã¡ã¯ã€ãã«ã¡ã¯ãã³ãã·ã¹ãããã£ãã¯ã»ã¬ãã¥ãŒïŒæé«ã¬ãã«ã®èšŒæ ïŒããããã®çµæããã€ãã«ã¡ã¯ãã³ã远å ããããšã§ãéåžžã®æ²»çãšæ¯èŒããŠææãªèšåºçæ¹åãåŸãããã
WHOã®èŠè§£ãæ£åœåãããããªãå察ã®çµæã瀺ã質ã®é«ããšããã³ã¹ã¯ã©ãã«ããã®ã ãããïŒ
ããããçåã«ã€ããŠã¯äžåçããªããŸãŸãæ²»çè¬ã®å¹æãçé¢ç®ã«æ€èšŒããªãã§ããäžçïŒæ¿åºïŒãã¹ã³ãïŒãã以å€ã®èª°ãïŒïŒããæ¬æ°ã§æ°åã³ãããŠã€ã«ã¹ãæ²æ» ããããšæã£ãŠãããªã©ãšä¿¡ããããã§ããããïŒé°è¬è«è ãšããã人ã ã®å£°ã«ããè³ãåŸããŠã¿ãå¿ èŠããããšæããŸãã
ãããŠãä»ãéã®ããšãèµ·ãã£ãŠãããšèšããŸããé°è¬è«è ãšå¯Ÿæ¥µã«ãããã¯ã¯ãã³æšé²è åŽã®æ¹ã«ãç¡çãªããžãã¯ããŸããéãããã«ãªã£ãŠããŸããã
æ¥æ¬ã§ãã¯ã¯ãã³æ¥çš®ãé²ãã«ã€ããŠãã¯ã¯ãã³èšŒææžã®è°è«ãªã©ãçŸå®å³ã垯ã³ãŠããŸããã
ããããæ¢ã«äœåºŠãèšäºã«ããŠããéããã¯ã¯ãã³èšŒææžã¯ããããŸããã
ã¯ã¯ãã³èšŒææžããã£ãŠãè¡åãèªç±ã«ãªããªã©ãšããã®ã¯ãå¹»æ³ä»¥å€ã®äœç©ã§ããããŸããããããç¡çç¶ææè ãèªç±ã«åºæ©ãããã«ãªãããšã§ãç¶æ³ãæªåããããšããäºæ³ãåŸãŸãã
ã¯ã¯ãã³ã®æ²»éšãååã§ã¯ãããŸãããåœå ã§ã¯ãããã«200åè¶³ããã®èšåºè©Šéšããã£ãŠãç¹äŸæ¿èªãåããŠããã«éããŸãããåœç¶ãåããŠã®è©Šã¿ã§ããmRNAã¯ã¯ãã³ã®äžé·æçãªåœ±é¿ãªã©ã«ã€ããŠã¯ãå®éã®ãšããããŸã äœãåãã£ãŠããªãç¶æ ã§ãããããªãã®ãæ¿åºããã¹ã³ãããããããäžèœã§ãããã®åŠãå§äŒããŠãå€ãã®åœæ°ãæå ã«ãšæãšããšããŠããã®ããä»ã®ã¯ã¯ãã³ãªã®ã§ãã
ã¯ã£ããèšããŸããä»ã®ã¯ã¯ãã³ä¿¡å¥ã¯äžçš®ã®ã«ã«ãã§ããã¯ã¯ãã³ã«ã«ããšãããã¹ãã§ããæ¿åºããã¹ã¡ãã£ã¢ãèšãããŸãŸãã¯ã¯ãã³ãä¿¡ãããã¯ã¯ãã³çä¿¡è ããã¡ãçãŸããŠããŠããç¶æ³ã«ãããšæããŸãã
ä»®ã«ä»äººã®ããšãé°è¬è«è ãšåŒã¶äººã ããããšãããããŸãèªããã¯ã¯ãã³ã«ã«ãã§ãããšèªããã¹ãã§ããç§ã¯ãé°è¬è«è ã§çµæ§ã§ããä»åŸãã¯ã¯ãã³ã«ã«ãã®æ¹ã ããã¯ã¯ãã³ãæã£ãçµæãã©ã®ããã«ãªã£ãŠããã®ããå«ããŠããã£ããæéããããŠã¿ãŠãããããšæããŸãã